tbuckley/cabot-search huggingface dataset:
Immunoelectrophoretic Studies of Serums from Mice Carrying Two Transplantable Plasma-Cell Leukemias&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: J. Clausen, J. Heremans, M. Th. Heremans, R. Rask-Nielsen
Journal: JNCI Journal of the National Cancer Institute (1959)

Immunoelectrophoretic investigations were made on serums from mice carrying 2 plasma-cell leukemia vid. transplantation lines 20 and 36 associated respectively with development of β-paraprotein and γ-paraprotein with M-mobility. In line 20, the β-paraprotein-developing leukemia, this abnormal protein fraction immunoelectrophoretically belonged to the faster part of the normal mouse γ-globulin, thus labeling this leukemia immunochemically as γ-type with β-mobility. Another abnormality was increase and faster mobility of β2-III-globulin, and increase of β2-I-fraction. Line 36 divided in the first transfer into 2 sublines, 36 y and 36 x, with and without γ-paraprotein of M-type, respectively. The serological characteristics within each line remained unchanged for several passages. In paraprotein-containing serum from line 36 y, significant increase in the intermediate part of the γ-globulin bow was seen. In serums from line 36 x, this γ-bow was fainter than in normal serum. In line 36 y, the β2-III-globulin showed the same increase and abnormal velocity found in line 20. Increase in β2-I-fraction was more pronounced than in line 20. In line 36 x the same abnormality of β2-III, but no increase in β2-I, was detected. In all 3 transplantation lines, parts of the γ-bow not involved in paraprotein transformation were reduced in concentration. The significance of changes observed in β2-III- and β-I-fractions and the correlation of these changes to the leukemic process is unknown. The findings were discussed and were compared to electrophoretic patterns seen in human beings with myelomas.
Case 6-1971
Authors: Conger Williams, Walter G.J. Putschar
Journal: New England Journal of Medicine (1971)

Presentation of CaseA 70-year-old woman was admitted to the hospital because of dyspnea.She had been well until 18 years previously, when rheumatoid arthritis occurred, leading to multiple joint deformities. During the 10 years before admission she received a preparation containing prednisolone, 1.5 to 2.25 mg daily. Six years before entry a cushingoid appearance was observed, and a systolic murmur was heard. For several months before entry she complained intermittently of vague pain in the chest. Two months before admission dyspnea developed, and she slept on two pillows thereafter. For several weeks she had a cough, and during the . . .
Gene expression of MLH1 related to microsatellite instability, immuno-histochemistry, and promoter hypermethylation in colorectal cancer
Authors: L. H. Jensen, A. Jakobsen, H. Kuramochi, B. Liu, C. L. Stephen, D. G. Crüger, A. Aggerholm, J. Lindebjerg, P. V. Danenberg, K. D. Danenberg
Journal: Journal of Clinical Oncology (2006)

3601 Background: The subgroup of highly microsatellite instable (MSI-H) colorectal cancers (CRC), is well described with DNA microsatellite and immuno-histochemistry (IHC) analyses. MSI-H CRCs are most often caused by hypermethylation inactivation of MLH1 or to a lesser extent by hereditary mutations in this or other mismatch repair genes. Microsatellite analysis and IHC are qualitative rather than quantitative methods. Reports showing that MMR deficient CRC has a favorable prognosis and that these cancers may respond less to chemotherapy may be more informative if based on a quantitative method instead. The aim of the present study was to correlate the expression of MLH1 to microsatellite analysis, promoter hypermethylation, and IHC. Methods: Sections of paraffin-embedded tumors from 206 unselected consecutive patients with CRC were microdissected and RNA was isolated and reverse-transcribed to cDNA. The relative gene expression of MLH1 was measured with real-time PCR. DNA from tumor and blood was examined with five standard microsatellite markers to find length mutations indicating instability. Tumor DNA was further analyzed with a methylation specific PCR in the C region of the MLH1 promoter. Protein expression of MLH1 was analyzed with IHC. Results: For all quantifiable tumors the median (and lower and upper quartiles) of the relative MLH1 gene expression was 0.90 (0.68, 1.42). For MSI-H tumors, defined as presense of instability in at least two markers or lack of protein expression with IHC, the median was 0.36 (0.26, 0.56). For microsatellite stable cancers the median was 0.96 (0.73, 1.44), p&lt;0.0001 (Wilcoxon test). Median and quartiles of MLH1 expression in hypermethylated and non-methylated tumors was 0.31 (0.26, 0.45) and 0.96 (0.73, 1.43) respectively (p&lt;0.0001). Relative MLH1 expression in MSI-H tumors range up to 0.64. Fourteen % of MSS tumors are in this range, too. Conclusions: In this large unselcted group of CRC patients we found a significant relation between low gene expression, MSI-H, MLH1-hypermethylation and negative IHC. We further identify a subgroup of MSS patients with low gene expression of MLH1 and suggest this quantitative marker in studies of prognosis and treatment effect. [Table: see text]
Assessment of laparoscopic stomach preserving surgery with sentinel basin dissection compared with standard gastrectomy with lymphadenectomy in early gastric cancer: A study protocol of a multicenter randomized phase III clinical trial (SENORITA trial).
Authors: Keun Won Ryu, Ji Yeon Park, Young Woo Kim, Byung-Ho Nam, Young Joon Lee, Sang-Ho Jeong, Ji-Ho Park, Hoon Hur, Sang Uk Han, Jae-Seok Min, Ji Yeong An, Woo Jin Hyung, Gyu Seok Cho, Gui Ae Jeong, Oh Jeong, Young-Kyu Park, Mi Ran Jung, Hong Man Yoon, Bang Wool Eom
Journal: Journal of Clinical Oncology (2016)

TPS179 Background: Along with marked increase in early gastric cancer (EGC) in Eastern countries, there has been an effort to adopt sentinel node concept in EGC to reduce immediate postoperative complications and preserve gastric function. Based on the promising results from the previous quality control study prior to phase III trial, this prospective multicenter randomized controlled trial aimed to elucidate the oncologic safety of laparoscopic stomach-preserving surgery with sentinel basin dissection (SBD) compared to standard laparoscopic gastrectomy. Methods: This trial is an investigator-initiated, open-label, multicenter randomized controlled phase III trial with non-inferiority design. Patients diagnosed with a single lesion of clinical stage T1N0M0 gastric adenocarcinoma with a diameter of 3cm or less are eligible for the present study. A total of 580 patients (290 per each group) will be randomized to either laparoscopic stomach-preserving surgery with SBD or standard surgery. The primary end-point is 3-year disease-free survival (DFS) and the secondary endpoints include postoperative morbidity and mortality, quality of life, and 5-year DFS and overall survival. The qualified investigators who completed the prior quality control study are exclusively allowed to participate in this phase III clinical trial. Discussion: The proposed trial is expected to verify whether laparoscopic stomach-preserving surgery with SBD achieves the similar oncologic outcomes and improved quality of life compared to the standard gastrectomy in EGC patients. Clinical trial information: NCT01804998.
Growth Studies on Sarcoma 37 in Mice
Authors: Abraham Goldin, Stewart R. Humphreys, John M. Venditti, Don Dennis, Nathan Mantel
Journal: JNCI Journal of the National Cancer Institute (1956)

Journal Article Growth Studies on Sarcoma 37 in Mice Get access Abraham Goldin, Abraham Goldin Laboratory of Chemical Pharmacology and Biometry and Epidemiology Branch, National Cancer Institute2Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Stewart R. Humphreys, Stewart R. Humphreys Laboratory of Chemical Pharmacology and Biometry and Epidemiology Branch, National Cancer Institute2Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar John M. Venditti, John M. Venditti Laboratory of Chemical Pharmacology and Biometry and Epidemiology Branch, National Cancer Institute2Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Don Dennis, Don Dennis Laboratory of Chemical Pharmacology and Biometry and Epidemiology Branch, National Cancer Institute2Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Nathan Mantel Nathan Mantel Laboratory of Chemical Pharmacology and Biometry and Epidemiology Branch, National Cancer Institute2Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 16, Issue 5, April 1956, Pages 1207–1220, https://doi.org/10.1093/jnci/16.5.1207 Published: 01 April 1956 Article history Received: 18 October 1955 Published: 01 April 1956
Cancer of the Bladder and Infestation with &lt;italic&gt;Schistosoma hematobium&lt;/italic&gt;
Authors: Piero Mustacchi, Michael B. Shimkin
Journal: JNCI Journal of the National Cancer Institute (1958)

Cancer of the Bladder and Infestation with Schistosoma hematobium Piero Mustacchi, Piero Mustacchi Biometry Branch, National Cancer Institute,3Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael B. Shimkin Michael B. Shimkin Biometry Branch, National Cancer Institute,3Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar 2Present address: Department of Medicine and Preventive Medicine (Epidemiology), University of California School of Medicine, San Francisco 22, Calif. 3National Institutes of Health, Public Health Service, U. S. Department of Health, Education, and Welfare. Author Notes JNCI: Journal of the National Cancer Institute, Volume 20, Issue 4, April 1958, Pages 825–842, https://doi.org/10.1093/jnci/20.4.825 Published: 01 April 1958 Article history Received: 04 November 1957 Published: 01 April 1958
Enzymatic Hydrolysis of Benzoylarginineamide in Normal and Neoplastic Tissues
Authors: Jesse P. Greenstein, Florence M. Leuthardt
Journal: JNCI Journal of the National Cancer Institute (1946)

Journal Article Enzymatic Hydrolysis of Benzoylarginineamide in Normal and Neoplastic Tissues Get access Jesse P. Greenstein, Jesse P. Greenstein principal biochemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Florence M. Leuthardt Florence M. Leuthardt junior biochemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 6, Issue 4, February 1946, Pages 203–206, https://doi.org/10.1093/jnci/6.4.203 Published: 01 February 1946
TAF10 Interacts with GATA1 Transcription Factor and Controls Mouse Erythropoiesis
Authors: Petros Papadopoulos, Laura Gutierrez, Jeroen Demmers, Dimitris Papageorgiou, Elena Karkoulia, John Strouboulis, Reinier van der Linden, Elisabeth Scheer, Farzin Pourfarzad, Dick Dekkers, Peter Vandenberghe, Sjaak Philipsen, Frank Grosveld, László Tora
Journal: Blood (2014)
Positron emission tomographic measurement of bone marrow blood flow to the pelvis and lumbar vertebrae in young normal adults [published erratum appears in Blood 1994 Nov 15;84(10):3602]
Authors: D Kahn, GJ Weiner, S Ben-Haim, LL Ponto, MT Madsen, DL Bushnell, GL Watkins, EA Argenyi, RD Hichwa
Journal: Blood (1994)
PNR-32UPDATE OF DIAGNOSTICS OF PRIMITIVE NEUROECTODERMAL TUMOURS OF THE CNS - NEUROPATHOLOGICAL RE-EVALUATION OF 99 CASES
Authors: Torsten Pietsch, Dominique Figarella-Branger, Cynthia Hawkins, Felice Giangaspero, Thomas S. Jacques, Marco Gessi, Peter Burger, Christine Haberler
Journal: Neuro-Oncology (2016)

PNR-32. UPDATE OF DIAGNOSTICS OF PRIMITIVE NEUROECTODERMAL TUMOURS OF THE CNS NEUROPATHOLOGICAL RE-EVALUATION OF 99 CASES Torsten Pietsch1, Dominique Figarella-Branger2, Cynthia Hawkins3, Felice Giangaspero4, Thomas S. Jacques5, Marco Gessi1, Peter Burger6, Christine Haberler7, and for the Internatonal CNS-PNET working group1; University of Bonn, Bonn, Germany; University of Marseille, Marseille, France; The Hospital for Sick Children, Toronto, Canada; University of Rome, Rome, Italy; University of London, London, UK; Johns Hopkins University, Baltimore, USA; University of Vienna, Vienna, Austria Recent analysis of tumours historically diagnosed as CNS-PNET by epigenetic profiling has led to the hypothesis that such cases may represent morphological mimics of CNS-PNET but can be largely assigned to other tumour entities, and that CNS-PNET are frequently misclassified by neuropathological diagnostics. As part of an international effort to collect and re-analyze CNS-PNET, 99 tumours diagnosed as CNS-PNET or pineoblastoma in the last 2 decades in 9 European countries were reviewed according to today’s standards of neuropathological diagnostics. 46% of cases were confirmed as CNS-PNET; of these, 68% were diagnosed as ETMR (including ependymoblastoma/ medulloepithelioma), and 32% as other CNS-PNET (CNS-PNET, NOS (n 1⁄4 11), CNSneuroblastoma (n 1⁄4 3) and CNS-ganglioneuroblastoma (n 1⁄4 2)). 54% of tumours were defined as other entities includingpineal parenchymal tumours (pineoblastoma/PPID; n 1⁄4 12), (anaplastic) ependymomas (n 1⁄4 7), PXA (n 1⁄4 2), diffuse high-grade gliomas (n 1⁄4 15), ATRT (n 1⁄4 3), mesenchymal tumours /sarcomas (n 1⁄4 7), germ cell tumour (n 1⁄4 1) and medulloblastoma (n 1⁄4 1), and 5 tumours were not classifiable, mostly because of insufficient biopsy material. A marker panel was defined for an optimized approach for the assessment of CNS-PNETs and tumours mimicking these neoplasms in routine neuropathological diagnostic workup. This study shows that (1) today’s diagnostic repertoire allows assignment of CNS-PNET cases, and (2) retrospective cohorts treated in neuro-oncological studies have to be re-analyzed to allow meaningful conclusions on effectiveness of specific treatment modalities. This cohort will be used to cross-validate assignment to tumour entities by epigenetic profiling and the associated clinical datawill be re-analyzed inan internationalmeta-analysis. Supported by the German Children’s Cancer Foundation. Neuro-Oncology 18:iii7–iii15, 2016. doi:10.1093/neuonc/now067.27 #The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Glenn Horner Algire 1907–1958
Authors: W R EARLE
Journal: JNCI Journal of the National Cancer Institute (1958)

Glenn Horner Algire 1907–1958 Get access Wilton R. Earle Wilton R. Earle Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 21, Issue 3, September 1958, Pages iii–vi, https://doi.org/10.1093/jnci/21.3.iii Published: 01 September 1958
Effects of Estrogen and/or Pituitary Graft on Nucleic Acid Synthesis of Carcinogen-Induced Mammary Tumors in Rats2
Authors: Hiroshi Nagasawa, Reiko Yanai
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Effects of Estrogen and/or Pituitary Graft on Nucleic Acid Synthesis of Carcinogen-Induced Mammary Tumors in Rats Get access Hiroshi Nagasawa, Hiroshi Nagasawa Search for other works by this author on: Oxford Academic PubMed Google Scholar Reiko Yanai Reiko Yanai Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 52, Issue 4, April 1974, Pages 1219–1222, https://doi.org/10.1093/jnci/52.4.1219 Published: 01 April 1974 Article history Received: 26 September 1973 Accepted: 09 January 1974 Published: 01 April 1974
Diaphragm and Laryngeal FDG Uptake With Hiccups
Authors: Madhur K. Srivastava, Avani S. Jain, Venkat Panneer, Indirani Muthukrishnan, Shelley Simon
Journal: Clinical Nuclear Medicine (2015)

F-FDG PET/CT study is a well-established investigation in diagnosis, treatment evaluation, and follow-up of malignant tumors. It is very important to know the normal biodistribution and physiologic uptake of F-FDG to prevent it from confusing as malignant disease. This article describes unusual but physiological uptake in the laryngeal and diaphragmatic muscles in a patient presenting as metastatic adenocarcinoma with unknown primary having hiccups.
Access to anonymised patient data: corners cannot be cut if patient confidence is to be maintained
Authors: Phil Booth
Journal: BMJ (2015)

It’s always unfortunate when any research project fails to deliver the promise in its proposal, but it seems odd for Filippon to rail against the custodian of the nation’s medical histories, the Health and Social Care Information Centre (HSCIC).1 

Filippon’s institution could not give the required assurance that it could protect data to the standard the public expects. The …
Reappraisal and resilience to stress: Context must be considered
Authors: Allison S. Troy
Journal: Behavioral and Brain Sciences (2015)

Abstract Kalisch et al. propose that positive reappraisal constitutes a resilience mechanism for highly stressed individuals. Both empirical and theoretical accounts suggest that this claim is too simplistic – the relationship between reappraisal and resilience depends on context. Indeed, there may be contexts in which reappraisal leads to harm, not resilience. Future research should examine multiple regulatory processes as well as context.
Prognostic role of PD-L1 polymorphism according to MSI in colon cancer.
Authors: Sang-Hee Cho, Min-Ho Shin, Sun-Seog Kweon, Hee-Nam Kim, Hyung-jung Shim, Jun Eul Hwang, Woo Kyun Bae, Ik-Joo Chung
Journal: Journal of Clinical Oncology (2015)

e14578 Background: To evaluate the prognostic role of PD-L1 polymorphism associated with microsatellite status in patients with surgically resected stage III colon cancer Methods: PD-L1 polymorphism was checked in peripheral blood from 273 patients who diagnosed as stage III colon cancer and received curative resection. Genomic DNA was extracted from blood which was drawn before operation. PD-L1 polymorphism (rs822339) genotyping was carried out using high-resolution melting (HRM) analysis and microsatellinte instability (MSI) was checked using PCR. Results: In total 273 patients, 47 patients (17.2%) were homozygous for Gly (G/G), with 142 heterozygous (A/G, 52.0%) and 84 homozygous (A/A, 30.8%) for Arg in PD-L1. No significant association was found between clinical or histopathologic tumor characteristics and PD-L1 genotype. MSI was shown in 25 (9.2%) patients and it was less frequent in G/G (n= 2) than Arg carriers (A/G or AA; n= 23, p= 0.157). In survival analysis, patients given oxaliplatin regimen showed better trend of DFS (p= 0.089) and significant improved OS (p= 0.001) than non-oxaliplatin regimen as an adjuvant treatment. According to subgroup analysis in non-oxaliplatin treated group, G/G (p= 0.074) and microsatellite stable (MSS, p= 0.026) showed better OS compared to Arg carriers or MSI. Especially, MSS showed favorable OS than MSI in Arg carriers (p= 0.016), but G/G had better OS than Arg carriers regardless of MSI status among these patients. In contrary, there is a similar outcome in oxaliplatin treated group without affecting PD-L1 polymorphism or MSI status. In multivariate analysis, high risk group (Arg carriers and MSI) was an independent prognostic factor for OS with other factors such as age ( ≥ 70Y), N2 stage, poorly differentiation, absence of lymphocyte response, non-oxaliplatin containing adjuvant chemotherapy. Conclusions: PD-L1 polymorphism and MSI are associated with prognosis in stage III colon cancer, and oxaliplatin overcome their poor prognosis. This result could guide the individual selection for adjuvant chemotherapy in clinical practice and the clues for understanding the interaction between cancer cells and immune microenvironment.
Case 11-1964
Authors: John D. Stoeckle, Benjamin Castleman
Journal: New England Journal of Medicine (1964)

Presentation of CaseAn eighty-one-year-old man entered the hospital because of dyspnea.The patient had been well until the development of exertional dyspnea, anorexia and weakness four months previously. A physician observed pallor and prescribed hematinics, but the dyspnea progressed, and orthopnea and chest pain occurred. Four days before admission ankle edema appeared. There was no history of paroxysmal dyspnea, exertional chest pain, hemoptysis, respiratory infection, hypertension or diabetes. He had smoked two packages of cigarettes daily for over fifty years and had formerly consumed alcohol in large quantities. He owned two parakeets, one of which had recently died.Physical . . .
The Natural History of Chronic Otitis Media
Authors: M A Baumann, J A Libnoch
Journal: New England Journal of Medicine (1982)

To the Editor: Australian Aboriginal people have a very high prevalence of chronic ear disease. Although this condition rarely leads to surgical complications, we have studied it because of the effects of poor hearing on education. A survey was undertaken at the settlement of Woorabinda in central Queensland, Australia, to determine the prevalence of the disease in the community. The settlement had a population of 450. They all lived in wooden houses with electricity and piped water. There was a government school for children 5 through 14 years of age. A team comprising an otolaryngologist, an audiologist, and a.
Difference between plasma N- and C-terminally directed beta-endorphin immunoreactivity in infantile autism
Authors: M Leboyer, M P Bouvard, C Recasens, A Philippe, M Guilloud-Bataille, D Bondoux, F Tabuteau, M Dugas, J Panksepp, J M Launay
Journal: American Journal of Psychiatry (1994)

The authors investigated whether there is excessive opioid activity in infantile autism by measuring plasma beta-endorphin in patients with autism compared with patients who had Rett's syndrome and normal comparison subjects.Radioimmunoassays for beta-endorphin using C-terminally and N-terminally directed antisera were applied to plasma samples from 67 children who met both DSM-III-R and ICD-10 diagnostic criteria for infantile autism, 22 girls with Rett's syndrome, and 67 normal children matched in age and sex with the children with autism.Median N-terminally directed beta-endorphin immunoreactivity appeared to be slightly lower in subjects with autism (7 pg/ml) and clearly higher in the girls with Rett's syndrome (40 pg/ml) than in the comparison subjects (9 pg/ml). Median C-terminally directed beta-endorphin immunoreactivity was higher in the girls with Rett's syndrome (35 pg/ml) and much higher in patients with autism (70 pg/ml) than in comparison subjects (8 pg/ml).These findings demonstrate the existence of a wide discrepancy between C- and N-terminally directed beta-endorphin immunoreactivity among children with autism. Despite the fact that the nature of the antigen recognized in the plasma of autistic children by the C-terminally directed anti-beta-endorphin serum remains to be characterized, the difference between C- and N-terminally directed beta-endorphin immunoreactivity might suggest an abnormal processing of the pro-opiomelanocortin gene in infantile autism.